Abstract Number: 2568 • ACR Convergence 2023
First Breakthrough COVID-19 Infection Following Two SARS-CoV-2 Vaccinations Among Primary Systemic Vasculitis Patients
Background/Purpose: Primary systemic vasculitis (PSV) patients on immunosuppression are at higher risk of adverse outcomes following COVID-19 infection and often mount suboptimal vaccine responses to…Abstract Number: 0203 • ACR Convergence 2023
Projecting the Impact on Clinical Outcomes in ANCA-Associated Vasculitis of Delaying Retreatment with Rituximab for Vaccine Optimization
Background/Purpose: Rituximab (RTX) is effective for maintaining remission in ANCA-associated vasculitis (AAV) but increases risks for vaccine-preventable severe infections and reduces the immune response to…Abstract Number: 0699 • ACR Convergence 2023
T Cell Subset Analysis in Patients with Large-Vessel Vasculitis
Background/Purpose: Large-vessel vasculitis (LVV) is characterized by granulomatous inflammation of the aorta and its major branches. The two major forms are giant cell arteritis (GCA)…Abstract Number: 0801 • ACR Convergence 2023
LncRNA PIGL-217 Regulates Th17 Differentiation by Targeting miR-5008-5p and Suppressing FoxO1 in Behçet’s Disease
Background/Purpose: Dysregulated Th17 cells are implicated in Behçet's disease (BD). However, the underlying mechanism remains unclear. Here we aim to elucidate the mechanism of forkhead…Abstract Number: 1542 • ACR Convergence 2023
The Burden of Multimorbidity in ANCA-Associated Vasculitis: A Cohort Study
Background/Purpose: With improvements in the risks of relapse and mortality in ANCA-associated vasculitis (AAV), a better understanding of disease- and treatment-related complications is necessary to…Abstract Number: 1626 • ACR Convergence 2023
Clinical Presentation, Disease Course and 12-month Outcomes in Childhood Polyarteritis Nodosa: A PedVas Study
Background/Purpose: Childhood polyarteritis nodosa (PAN) is a systemic vasculitis with necrotizing inflammation that typically affects small and medium-sized arteries. The clinical presentation is variable; it…Abstract Number: 2390 • ACR Convergence 2023
Characterization of Senescent Cells in Temporal Arteries of Patients with Giant Cell Arteritis Reveal an Inflammatory Phenotype and Strong Dependence from IL-6
Background/Purpose: Age is the strongest risk factor of giant cell arteritis (GCA), implying a possible pathogenetic role of cellular senescence. So far, no studies have…Abstract Number: 2417 • ACR Convergence 2023
Influence of Histological Tempol Artery Biopsy Findings on Outcomes of Biopsy-proven Giant Cell Arteritis in Italian Patients : A Long Single Center Follow-up Study
Background/Purpose: Few studies have evaluted the influence of histological features of temporal artery biopsy (TAB) on disease outcome in giant cell arteritis (GCA) patients. Our…Abstract Number: 2599 • ACR Convergence 2023
Study of the Role of interleukin-17 in Giant Cell Arteritis
Background/Purpose: Giant cell arteritis (GCA) is a vasculitis in which Th17 cells have been identified in excess in lesions and in the blood of patients.…Abstract Number: 031 • 2023 Pediatric Rheumatology Symposium
Multisystem Inflammatory Syndrome in Children Phenotypes Vary Between SARS-CoV-2 Variants
Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is a serious complication associated with COVID-19, presenting as a hyperinflammatory disorder characterized by fever and multiorgan dysfunction.…Abstract Number: 045 • 2023 Pediatric Rheumatology Symposium
Patient Reported Outcomes in Pediatric Vasculitis
Background/Purpose: Vasculitis is a group of multisystem, often relapsing diseases that can affect patients through disease activity, damage, and treatment toxicity. Vasculitis in adults often…Abstract Number: 060 • 2023 Pediatric Rheumatology Symposium
Are the Levels of Cytokines Good Biomarkers for Smoldering Disease Activity in Childhood-Takayasu Arteritis?
Background/Purpose: Biomarkers for disease activity in adult Takayasu arteritis (TA) have been studied exhaustively, but there are inconsistencies among the studies (1). Childhood-TA (c-TA) differs…Abstract Number: 061 • 2023 Pediatric Rheumatology Symposium
Variation in Treatment Approaches to IVIG- Refractory Kawasaki Disease (KD) Among Pediatric Rheumatologists: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Treatment of Refractory KD Survey
Background/Purpose: Kawasaki disease (KD) is the leading cause of acquired heart disease in children in North America. Initial treatment with IVIG has significantly reduced the…Abstract Number: 071 • 2023 Pediatric Rheumatology Symposium
Clinical Manifestations and Management of Takayasu Arteritis: A Single Center Pediatric Cohort
Background/Purpose: Takayasu arteritis (TA) is a rare granulomatous vasculitis that affects large vessels, including the aorta, its major branches, and the pulmonary artery. Data on…Abstract Number: L17 • ACR Convergence 2022
Evaluating the Safety and Factors Associated with Treatment Cessation in Takayasu Arteritis
Background/Purpose: Immunosuppression in Takayasu Arteritis (TA) reduces the risk of arterial damage and disease progression. However, long-term use of glucocorticoids (GC) and other immunosuppressants carries…
- « Previous Page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- …
- 41
- Next Page »